ipilimumab,nivolumab
bms
[]
#gi23 checkmate 649 (36 mo f/u): nivo + chemo vs. chemo in advanced eg adeno maintained os benefit with sustained separation of survival curves (for both pdl1 cps &gt; 5 and all randomized). rr improved regardless of pdl1 
Oncologist | Focus on #NETs | she/her 
Division Chief, GI Oncology @YaleCancer | Consultant Editor @JCO_ASCO |
Tweets mine | ASCO FCOI: https://t.co/UuqIAQ54sX